Sector News

Guido Oelkers appointed President and CEO at Sobi

May 5, 2017
Life sciences

Swedish Orphan Biovitrum AB today announces that Guido Oelkers has been appointed President and Chief Executive Officer effective as of 22 May 2017, succeeding Geoffrey McDonough.

Guido Oelkers joins Sobi from his previous role as CEO at BSN Medical GmbH. He has extensive experience from pharmaceutical and health care companies including a role as President and CEO of the Swedish medtech company Gambro, CEO of the specialty pharmaceutical company Invida and a number of executive commercial operations roles in companies such as Nycomed, DKSH Group and Aventis (formerly Hoechst), where he began his career. Guido Oelkers was also a member of the Board of Directors for Meda. Guido Oelkers was born in 1965 and holds a PhD in Strategic Management from the University of South Australia and a Master of Economics from South Bank University, London. He complemented his postgraduate studies in Economics at London School of Economics and Political Science.

“We are delighted to announce Guido’s appointment. He has created substantial shareholder value in his various positions. Guido is a results-driven strategist and an entrepreneur at heart who has demonstrated impressive resourcefulness and creativity in his previous roles. Guido is the right person to further develop Sobi’s strategy as a pioneering biotechnology company, expanding upon the journey for our successful global brands, and realise the remarkable potential in our haemophilia franchise,” says Håkan Björklund, Chairman of Sobi. “The Board would also like to thank Geoffrey McDonough for his significant contribution and the remarkable value he has created during his term as CEO at Sobi.”

“Sobi is a unique company in the rare disease field. With a strong heritage, the company has been on an exciting journey over the years. I am delighted to be appointed CEO and look forward to work with the team at Sobi to continue on this path of strong commercial potential, innovation and development in order to serve rare disease patients and their families,” says Guido Oelkers.

Guido Oelkers is going to relocate to Stockholm, Sweden.

Source: Sobi™

 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”